Susan Dorman to Fluoroquinolones
This is a "connection" page, showing publications Susan Dorman has written about Fluoroquinolones.
Connection Strength
0.854
-
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PLoS One. 2016; 11(5):e0154778.
Score: 0.523
-
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009 Aug 01; 180(3):273-80.
Score: 0.080
-
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother. 2008 Nov; 52(11):4037-42.
Score: 0.077
-
The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med. 2003 Nov 13; 349(20):1977-8.
Score: 0.055
-
Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003 Dec 01; 37(11):1448-52.
Score: 0.055
-
Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. N Engl J Med. 2017 09 14; 377(11):1043-1054.
Score: 0.036
-
Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob Agents Chemother. 2014; 58(1):11-8.
Score: 0.027